Research programme: anticancer therapeutics - LegoChem Biosciences/Newgex

Drug Profile

Research programme: anticancer therapeutics - LegoChem Biosciences/Newgex

Alternative Names: I HSP90 (1) - LegoChem; I HSP90 (2) - LegoChem

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator LegoChem Biosciences; Newgex
  • Developer LegoChem Biosciences
  • Class
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top